文献速递消化系统肿瘤

二次探查手术联合HIPEC对比监测在高危结直肠腹膜转移患者中的随机三期研究

Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.
PubMed 文献 · Lancet Oncol · 2020-07-24

PROPHYLOCHIP-PRODIGE 15研究纳入150例高危结直肠腹膜转移患者,随机分为监测组或二次探查手术联合奥沙利铂HIPEC组。研究认为系统二次探查手术联合HIPEC未改善无病生存,监测仍为标准。

要点

  • 高危结直肠腹膜转移患者中,二次探查手术联合HIPEC未改善3年无病生存。
  • 手术组3-4级并发症发生率达41%,以腹腔出血/漏和血液学不良事件为主。
  • 标准监测在生存结局上仍为 adequate 且有效的策略。

核心结论

  • 系统二次探查手术联合奥沙利铂HIPEC对比标准监测未改善无病生存。
  • 目前对高危结直肠腹膜转移患者,必要的监测在生存结局方面似乎是充分且有效的。

研究设计与样本

  • 开放标签、随机、三期研究,在法国23家医院开展。
  • 纳入18-70岁、原发结直肠癌切除时存在同时性局限性腹膜转移、卵巢转移切除或穿孔肿瘤的患者。
  • 共150例患者按1:1随机分入监测组或二次探查手术联合HIPEC组(每组75例)。
  • 主要终点为3年无病生存,定义为随机至腹膜或远处复发或任何原因死亡的时间,按意向治疗分析。

主要发现

  • 未报告治疗相关死亡。
  • 二次探查手术组71例中29例(41%)发生3-4级并发症。
  • 最常见3-4级并发症为腹腔不良事件(出血、消化道漏)12/71(23%)和血液学不良事件13/71(18%)。

关键数值与推荐

  • 二次探查手术组HIPEC方案包括奥沙利铂460 mg/m2,或奥沙利铂300 mg/m2联合伊立替康200 mg/m2,加静脉氟尿嘧啶400 mg/m2;神经病变时单用丝裂霉素HIPEC 35 mg/m2。
  • 二次探查手术在6个月辅助全身化疗后无疾病复发迹象时进行,包括经剑突耻骨切口完整腹腔探查及可切除腹膜种植灶切除。
  • 监测按法国指南进行。

临床怎么用

  • 对于高危结直肠腹膜转移患者,不应常规采用系统二次探查手术联合HIPEC以改善生存。
  • 标准监测可作为该类患者的 adequate 且有效的策略。
  • 需权衡二次探查手术联合HIPEC的高3-4级并发症风险(41%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnosis and treatment of colorectal peritoneal metastases at an early stage, before the onset of signs, could improve patient survival. We aimed to compare the survival benefit of systematic second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC), with surveillance, in patients at high risk of developing colorectal peritoneal metastases. METHODS: We did an open-label, randomised, phase 3 study in 23 hospitals in France. Eligible patients were aged 18-70 years and had a primary colorectal cancer with synchronous and localised colorectal peritoneal metastases removed during tumour resection, resected ovarian metastases, or a perforated tumour. Patients were randomly assigned (1:1) to surveillance or second-look surgery plus oxaliplatin-HIPEC (oxaliplatin 460 mg/m2, or oxaliplatin 300 mg/m2 plus irinotecan 200 mg/m2, plus intravenous fluorouracil 400 mg/m2), or mitomycin-HIPEC (mitomycin 35 mg/m2) alone in case of neuropathy, after 6 months of adjuvant systemic chemotherapy with no signs of disease recurrence. Randomisation was done via a web-based system, with stratification by treatment centre, nodal status, and risk factors for colorectal peritoneal metastases. Second-look surgery consisted of a complete exploration of the abdominal cavity via xyphopubic incision, and resection of all peritoneal implants if resectable. Surveillance after resection of colorectal cancer was done according to the French Guidelines. The primary outcome was 3-year disease-free survival, defined as the time from randomisation to peritoneal or distant disease recurrence, or death from any cause, whichever occurred first, analysed by intention to treat. Surgical complications were assessed in the second-look surgery group only. This study was registered at ClinicalTrials.gov, NCT01226394. FINDINGS: Between June 11, 2010, and March 31, 2015, 150 patients were recruited and randomly assigned to a treatment group (75 per group). After a median follow-up of 50·8 months (IQR 47·0-54·8), 3-year disease-free survival was 53% (95% CI 41-64) in the surveillance group versus 44% (33-56) in the second-look surgery group (hazard ratio 0·97, 95% CI 0·61-1·56). No treatment-related deaths were reported. 29 (41%) of 71 patients in the second-look surgery group had grade 3-4 complications. The most common grade 3-4 complications were intra-abdominal adverse events (haemorrhage, digestive leakage) in 12 (23%) of 71 patients and haematological adverse events in 13 (18%) of 71 patients. INTERPRETATION: Systematic second-look surgery plus oxaliplatin-HIPEC did not improve disease-free survival compared with standard surveillance. Currently, essential surveillance of patients at high risk of developing colorectal peritoneal metastases appears to be adequate and effective in terms of survival outcomes. FUNDING: French National Cancer Institute.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Goéré D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020. PMID: 32717180. doi:10.1016/S1470-2045(20)30322-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。